{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:09:55Z","timestamp":1790266195951,"version":"4.1.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Immunol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1038\/s41577-020-00471-1","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T17:03:41Z","timestamp":1604336621000},"page":"727-738","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":126,"title":["Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2663-1551","authenticated-orcid":false,"given":"David S.","family":"Khoury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5593-9387","authenticated-orcid":false,"given":"Adam K.","family":"Wheatley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2134-610X","authenticated-orcid":false,"given":"Mitchell D.","family":"Ramuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5529-5542","authenticated-orcid":false,"given":"Arnold","family":"Reynaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5276-5094","authenticated-orcid":false,"given":"Deborah","family":"Cromer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1713-3056","authenticated-orcid":false,"given":"Kanta","family":"Subbarao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8539-4891","authenticated-orcid":false,"given":"Stephen J.","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4751-1831","authenticated-orcid":false,"given":"Miles P.","family":"Davenport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,2]]},"reference":[{"key":"471_CR1","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201181","volume":"217","author":"F Schmidt","year":"2020","unstructured":"Schmidt, F. et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J. Exp. Med. 217, e20201181 (2020). This paper presents a comprehensive description of two SARS-CoV-2 spike-pseudotyped platforms (HIV and VSV-based) and a replication-competent VSV\/SARS-CoV-2 chimeric virus for the quantification of neutralizing antibody responses.","journal-title":"J. Exp. Med."},{"key":"471_CR2","doi-asserted-by":"publisher","unstructured":"Greaney, A. J. et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2020.09.10.292078 (2020).","DOI":"10.1101\/2020.09.10.292078"},{"key":"471_CR3","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","volume":"182","author":"B Korber","year":"2020","unstructured":"Korber, B. et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 182, 812\u2013827 (2020).","journal-title":"Cell"},{"key":"471_CR4","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.cell.2020.08.012","volume":"182","author":"TN Starr","year":"2020","unstructured":"Starr, T. N. et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell 182, 1295\u20131310 (2020).","journal-title":"Cell"},{"key":"471_CR5","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","volume":"584","author":"L Liu","year":"2020","unstructured":"Liu, L. et al. Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike. Nature 584, 450\u2013456 (2020).","journal-title":"Nature"},{"key":"471_CR6","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","volume":"584","author":"SJ Zost","year":"2020","unstructured":"Zost, S. J. et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 584, 443\u2013449 (2020).","journal-title":"Nature"},{"key":"471_CR7","doi-asserted-by":"crossref","DOI":"10.1002\/cpmc.108","volume":"58","author":"F Amanat","year":"2020","unstructured":"Amanat, F. et al. An in vitro microneutralization assay for SARS-CoV-2 serology and drug screening. Curr. Protoc. Microbiol. 58, e108 (2020).","journal-title":"Curr. Protoc. Microbiol."},{"key":"471_CR8","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","volume":"38","author":"CW Tan","year":"2020","unstructured":"Tan, C. W. et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein\u2013protein interaction. Nat. Biotechnol. 38, 1073\u20131078 (2020).","journal-title":"Nat. Biotechnol."},{"key":"471_CR9","volume":"5","author":"KT Abe","year":"2020","unstructured":"Abe, K. T. et al. A simple protein-based surrogate neutralization assay for SARS-CoV-2. JCI Insight 5, e142362 (2020).","journal-title":"JCI Insight"},{"key":"471_CR10","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1080\/22221751.2020.1815589","volume":"9","author":"HL Xiong","year":"2020","unstructured":"Xiong, H. L. et al. Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells. Emerg. Microbes Infect. 9, 2105\u20132113 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"471_CR11","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","volume":"5","author":"M Letko","year":"2020","unstructured":"Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. 5, 562\u2013569 (2020).","journal-title":"Nat. Microbiol."},{"key":"471_CR12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3390\/v12050513","volume":"12","author":"KHD Crawford","year":"2020","unstructured":"Crawford, K. H. D. et al. Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays. Viruses 12, 513 (2020).","journal-title":"Viruses"},{"key":"471_CR13","doi-asserted-by":"publisher","unstructured":"Quinlan, B. D. et al. The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2020.04.10.036418 (2020).","DOI":"10.1101\/2020.04.10.036418"},{"key":"471_CR14","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cell.2020.07.012","volume":"182","author":"Q Li","year":"2020","unstructured":"Li, Q. et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell 182, 1284\u20131294 (2020).","journal-title":"Cell"},{"key":"471_CR15","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.chom.2020.06.020","volume":"28","author":"ME Dieterle","year":"2020","unstructured":"Dieterle, M. E. et al. A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition. Cell Host Microbe 28, 486\u2013496 (2020).","journal-title":"Cell Host Microbe"},{"key":"471_CR16","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.chom.2020.07.018","volume":"28","author":"JB Case","year":"2020","unstructured":"Case, J. B. et al. Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice. Cell Host Microbe 28, 465\u2013474 (2020). This study demonstrates the use of chimeric SARS-CoV-2\/VSV infection to assess neutralizing activity and viral escape in vitro.","journal-title":"Cell Host Microbe"},{"key":"471_CR17","doi-asserted-by":"crossref","first-page":"12455","DOI":"10.1128\/JVI.79.19.12455-12463.2005","volume":"79","author":"E Yuste","year":"2005","unstructured":"Yuste, E., Johnson, W., Pavlakis, G. N. & Desrosiers, R. C. Virion envelope content, infectivity, and neutralization sensitivity of simian immunodeficiency virus. J. Virol. 79, 12455\u201312463 (2005).","journal-title":"J. Virol."},{"key":"471_CR18","doi-asserted-by":"crossref","first-page":"13088","DOI":"10.1074\/jbc.M116.729210","volume":"291","author":"MC DeSantis","year":"2016","unstructured":"DeSantis, M. C., Kim, J. H., Song, H., Klasse, P. J. & Cheng, W. Quantitative correlation between infectivity and Gp120 density on HIV-1 virions revealed by optical trapping virometry. J. Biol. Chem. 291, 13088\u201313097 (2016).","journal-title":"J. Biol. Chem."},{"key":"471_CR19","doi-asserted-by":"crossref","first-page":"e00415","DOI":"10.1128\/JVI.00415-17","volume":"91","author":"A Stano","year":"2017","unstructured":"Stano, A. et al. Dense array of spikes on HIV-1 virion particles. J. Virol. 91, e00415\u2013e00417 (2017).","journal-title":"J. Virol."},{"key":"471_CR20","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nature04817","volume":"441","author":"P Zhu","year":"2006","unstructured":"Zhu, P. et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441, 847\u2013852 (2006).","journal-title":"Nature"},{"key":"471_CR21","doi-asserted-by":"crossref","first-page":"104882","DOI":"10.1016\/j.antiviral.2020.104882","volume":"181","author":"C Conzelmann","year":"2020","unstructured":"Conzelmann, C. et al. An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection. Antivir. Res. 181, 104882 (2020).","journal-title":"Antivir. Res."},{"key":"471_CR22","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/s41591-020-0995-0","volume":"26","author":"JA Juno","year":"2020","unstructured":"Juno, J. A. et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat. Med. 26, 1428\u20131434 (2020).","journal-title":"Nat. Med."},{"key":"471_CR23","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.1016\/j.vaccine.2008.09.026","volume":"26","author":"JE Martin","year":"2008","unstructured":"Martin, J. E. et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a phase I clinical trial. Vaccine 26, 6338\u20136343 (2008).","journal-title":"Vaccine"},{"key":"471_CR24","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41586-020-2787-6","volume":"586","author":"C Munoz-Fontela","year":"2020","unstructured":"Munoz-Fontela, C. et al. Animal models for COVID-19. Nature 586, 509\u2013515 (2020).","journal-title":"Nature"},{"key":"471_CR25","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-020-00763-0","volume":"12","author":"AD Davidson","year":"2020","unstructured":"Davidson, A. D. et al. Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein. Genome Med. 12, 68 (2020).","journal-title":"Genome Med."},{"key":"471_CR26","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1126\/science.abc4776","volume":"369","author":"A Chandrashekar","year":"2020","unstructured":"Chandrashekar, A. et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science 369, 812\u2013817 (2020). This study establishes that previously infected rhesus macaques show considerable protective immunity upon secondary challenge with SARS-CoV-2.","journal-title":"Science"},{"key":"471_CR27","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.chom.2020.03.023","volume":"27","author":"Y Kim","year":"2020","unstructured":"Kim, Y. et al. Infection and rapid transmission of SARS-CoV-2 in ferrets. Cell Host Microbe 27, 704\u2013709 (2020).","journal-title":"Cell Host Microbe"},{"key":"471_CR28","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41586-020-2342-5","volume":"583","author":"S Sia","year":"2020","unstructured":"Sia, S. et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature 583, 834\u2013838 (2020). This key study establishes the suitability of Syrian or golden hamsters as a highly suitable model for SARS-CoV-2 infection displaying hallmark pathogenesis and efficient transmission by direct contact or via aerosols.","journal-title":"Nature"},{"key":"471_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa325","author":"JF Chan","year":"2020","unstructured":"Chan, J. F. et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa325 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"471_CR30","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/nm.1974","volume":"15","author":"AJ Hessell","year":"2009","unstructured":"Hessell, A. J. et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15, 951\u2013954 (2009).","journal-title":"Nat. Med."},{"key":"471_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tube.2015.10.004","volume":"96","author":"S Sharpe","year":"2016","unstructured":"Sharpe, S. et al. Ultra low dose aerosol challenge with Mycobacterium tuberculosis leads to divergent outcomes in rhesus and cynomolgus macaques. Tuberculosis 96, 1\u201312 (2016).","journal-title":"Tuberculosis"},{"key":"471_CR32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0020249","volume":"2","author":"RR Regoes","year":"2005","unstructured":"Regoes, R. R., Longini, I. M., Feinberg, M. B. & Staprans, S. I. Preclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges. PLoS Med. 2, e249 (2005).","journal-title":"PLoS Med."},{"key":"471_CR33","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMp2020076","volume":"383","author":"ME Deming","year":"2020","unstructured":"Deming, M. E., Michael, N. L., Robb, M., Cohen, M. S. & Neuzil, K. M. Accelerating development of SARS-CoV-2 vaccines \u2014 the role for controlled human infection models. N. Engl. J. Med. 383, e63 (2020).","journal-title":"N. Engl. J. Med."},{"key":"471_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa935","author":"LC Nguyen","year":"2020","unstructured":"Nguyen, L. C. et al. Evaluating use cases for human challenge trials in accelerating SARS-CoV-2 vaccine development. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa935 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"471_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1290","author":"MM Levine","year":"2020","unstructured":"Levine, M. M. et al. Viewpoint of a WHO advisory group tasked to consider establishing a closely-monitored challenge model of COVID-19 in healthy volunteers. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa1290 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"471_CR36","first-page":"606","volume":"69","author":"L Hamner","year":"2020","unstructured":"Hamner, L. et al. High SARS-CoV-2 attack rate following exposure at a choir practice \u2014 Skagit County, Washington, March 2020. MMWR 69, 606\u2013610 (2020).","journal-title":"MMWR"},{"key":"471_CR37","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/S2666-5247(20)30089-6","volume":"5","author":"K Schlottau","year":"2020","unstructured":"Schlottau, K. et al. SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: an experimental transmission study. Lancet Microbe 5, e218\u2013e225 (2020).","journal-title":"Lancet Microbe"},{"key":"471_CR38","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"WJ Guan","year":"2020","unstructured":"Guan, W. J. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 382, 1708\u20131720 (2020).","journal-title":"N. Engl. J. Med."},{"key":"471_CR39","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054\u20131062 (2020).","journal-title":"Lancet"},{"key":"471_CR40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764","author":"JH Beigel","year":"2020","unstructured":"Beigel, J. H. et al. Remdesivir for the treatment of COVID-19 \u2014 preliminary report. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2007764 (2020).","journal-title":"N. Engl. J. Med."},{"key":"471_CR41","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMc2001737","volume":"382","author":"L Zou","year":"2020","unstructured":"Zou, L. et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N. Engl. J. Med. 382, 1177\u20131179 (2020).","journal-title":"N. Engl. J. Med."},{"key":"471_CR42","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(20)30196-1","volume":"20","author":"KK-W To","year":"2020","unstructured":"To, K. K.-W. et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect. Dis. 20, 565\u2013574 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"471_CR43","doi-asserted-by":"crossref","first-page":"102887","DOI":"10.1016\/j.ebiom.2020.102887","volume":"58","author":"P Domingo","year":"2020","unstructured":"Domingo, P. et al. The four horsemen of a viral apocalypse: the pathogenesis of SARS-CoV-2 infection (COVID-19). EBioMedicine 58, 102887 (2020).","journal-title":"EBioMedicine"},{"key":"471_CR44","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","volume":"20","author":"MZ Tay","year":"2020","unstructured":"Tay, M. Z., Poh, C. M., R\u00e9nia, L., MacAry, P. A. & Ng, L. F. P. The trinity of COVID-19: immunity, inflammation and intervention. Nat. Rev. Immunol. 20, 363\u2013374 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"471_CR45","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cell.2020.05.027","volume":"182","author":"R Jiang","year":"2020","unstructured":"Jiang, R. et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2. Cell 182, 50\u201358 (2020).","journal-title":"Cell"},{"key":"471_CR46","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-020-2324-7","volume":"585","author":"V Munster","year":"2020","unstructured":"Munster, V. et al. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. Nature 585, 268\u2013272 (2020).","journal-title":"Nature"},{"key":"471_CR47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008903","volume":"16","author":"AL Hartman","year":"2020","unstructured":"Hartman, A. L. et al. SARS-CoV-2 infection of African green monkeys results in mild respiratory disease discernible by PET\/CT imaging and shedding of infectious virus from both respiratory and gastrointestinal tracts. PLOS Pathog. 16, e1008903 (2020).","journal-title":"PLOS Pathog."},{"key":"471_CR48","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa851","author":"R Magleby","year":"2020","unstructured":"Magleby, R. et al. Impact of SARS-CoV-2 viral load on risk of intubation and mortality among hospitalized patients with coronavirus disease 2019. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa851 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"471_CR49","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41591-020-0869-5","volume":"26","author":"X He","year":"2020","unstructured":"He, X. et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat. Med. 26, 672\u2013675 (2020).","journal-title":"Nat. Med."},{"key":"471_CR50","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S1473-3099(20)30200-0","volume":"20","author":"F-X Lescure","year":"2020","unstructured":"Lescure, F.-X. et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect. Dis. 20, 697\u2013706 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"471_CR51","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/S0140-6736(99)02035-8","volume":"354","author":"B Ramratnam","year":"1999","unstructured":"Ramratnam, B. et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 354, 1782\u20131785 (1999).","journal-title":"Lancet"},{"key":"471_CR52","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41586-020-2312-y","volume":"583","author":"L Bao","year":"2020","unstructured":"Bao, L. et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 583, 830\u2013833 (2020). This key study confirms the pathogenicity of SARS-CoV-2 in human ACE2-transgenic mice including viral replication, weight loss and interstitial pneumonia.","journal-title":"Nature"},{"key":"471_CR53","doi-asserted-by":"crossref","first-page":"10096","DOI":"10.1128\/JVI.78.18.10096-10103.2004","volume":"78","author":"MP Davenport","year":"2004","unstructured":"Davenport, M. P., Ribeiro, R. M. & Perelson, A. S. Kinetics of virus-specific CD8+ T cells and the control of human immunodeficiency virus infection. J. Virol. 78, 10096\u201310103 (2004).","journal-title":"J. Virol."},{"key":"471_CR54","doi-asserted-by":"crossref","first-page":"9228","DOI":"10.1128\/JVI.79.14.9228-9235.2005","volume":"79","author":"MR Reynolds","year":"2005","unstructured":"Reynolds, M. R. et al. CD8+ T-lymphocyte response to major immunodominant epitopes after vaginal exposure to simian immunodeficiency virus: too late and too little. J. Virol. 79, 9228\u20139235 (2005).","journal-title":"J. Virol."},{"key":"471_CR55","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1080\/22221751.2020.1743767","volume":"9","author":"J Nie","year":"2020","unstructured":"Nie, J. et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg. Microbes Infect. 9, 680\u2013686 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"471_CR56","doi-asserted-by":"publisher","DOI":"10.1101\/2020.08.13.20157222","author":"KY Oguntuyo","year":"2020","unstructured":"Oguntuyo, K. Y. et al. Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus neutralization assay allows for cross-cohort comparisons of COVID-19 sera. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2020.08.13.20157222 (2020).","journal-title":"medRxiv"},{"key":"471_CR57","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","volume":"583","author":"D Pinto","year":"2020","unstructured":"Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290\u2013295 (2020).","journal-title":"Nature"},{"key":"471_CR58","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.chom.2020.06.021","volume":"28","author":"JB Case","year":"2020","unstructured":"Case, J. B. et al. Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2. Cell Host Microbe 28, 475\u2013485.e5 (2020).","journal-title":"Cell Host Microbe"},{"key":"471_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25986","author":"A Manenti","year":"2020","unstructured":"Manenti, A. et al. Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples. J. Med. Virol. https:\/\/doi.org\/10.1002\/jmv.25986 (2020).","journal-title":"J. Med. Virol."},{"key":"471_CR60","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","volume":"383","author":"KS Corbett","year":"2020","unstructured":"Corbett, K. S. et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N. Engl. J. Med. 383, 1544\u20131555 (2020).","journal-title":"N. Engl. J. Med."},{"key":"471_CR61","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.abc6284","volume":"369","author":"J Yu","year":"2020","unstructured":"Yu, J. et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369, 806\u2013811 (2020).","journal-title":"Science"},{"key":"471_CR62","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3201\/eid2607.200841","volume":"26","author":"NMA Okba","year":"2020","unstructured":"Okba, N. M. A. et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients. Emerg. Infect. Dis. 26, 1478\u20131488 (2020).","journal-title":"Emerg. Infect. Dis."},{"key":"471_CR63","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/s41590-020-0778-2","volume":"21","author":"E Winkler","year":"2020","unstructured":"Winkler, E. et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat. Immunol. 21, 1327\u20131335 (2020).","journal-title":"Nat. Immunol."},{"key":"471_CR64","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.cell.2020.06.011","volume":"182","author":"A Hassan","year":"2020","unstructured":"Hassan, A. et al. A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies. Cell 182, 744\u2013753 (2020).","journal-title":"Cell"},{"key":"471_CR65","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.chom.2020.05.020","volume":"28","author":"S Sun","year":"2020","unstructured":"Sun, S. et al. A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe 28, 124\u2013133 (2020).","journal-title":"Cell Host Microbe"},{"key":"471_CR66","doi-asserted-by":"crossref","first-page":"16587","DOI":"10.1073\/pnas.2018975117","volume":"117","author":"M Imai","year":"2020","unstructured":"Imai, M. et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl Acad. Sci. USA 117, 16587\u201316595 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"471_CR67","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1126\/science.abb7015","volume":"368","author":"J Shi","year":"2020","unstructured":"Shi, J. et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science 368, 1016\u20131020 (2020).","journal-title":"Science"},{"key":"471_CR68","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.abc5343","volume":"369","author":"W Deng","year":"2020","unstructured":"Deng, W. et al. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science 369, 818\u2013823 (2020).","journal-title":"Science"},{"key":"471_CR69","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1126\/science.abb7314","volume":"368","author":"B Rockx","year":"2020","unstructured":"Rockx, B. et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science 368, 1012\u20131015 (2020).","journal-title":"Science"},{"key":"471_CR70","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.14.096727","author":"C Finch","year":"2020","unstructured":"Finch, C. et al. Characteristic and quantifiable COVID-19-like abnormalities in CT- and PET\/CT-imaged lungs of SARS-CoV-2-infected crab-eating macaques (Macaca fascicularis). Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2020.05.14.096727 (2020).","journal-title":"bioRxiv"},{"key":"471_CR71","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.18.157933","author":"RV Blair","year":"2020","unstructured":"Blair, R. V. et al. Acute respiratory distress and cytokine storm in aged, SARS-CoV-2 infected african green monkeys, but not in rhesus macaques. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2020.06.18.157933 (2020).","journal-title":"bioRxiv"},{"key":"471_CR72","doi-asserted-by":"publisher","unstructured":"Woolsey, C. et al. Establishment of an African green monkey model for COVID-19. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2020.05.17.100289 (2020).","DOI":"10.1101\/2020.05.17.100289"},{"key":"471_CR73","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.05.136481","author":"DK Singh","year":"2020","unstructured":"Singh, D. K. et al. SARS-CoV-2 infection leads to acute infection with dynamic cellular and inflammatory flux in the lung that varies across nonhuman primate species. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2020.06.05.136481 (2020).","journal-title":"bioRxiv"},{"key":"471_CR74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1002767","volume":"8","author":"RR Regoes","year":"2012","unstructured":"Regoes, R. R. The role of exposure history on HIV acquisition: insights from repeated low-dose challenge studies. PLoS Comput. Biol. 8, e1002767 (2012).","journal-title":"PLoS Comput. Biol."},{"key":"471_CR75","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1089\/aid.2014.0238","volume":"30","author":"TR Henning","year":"2014","unstructured":"Henning, T. R. et al. Short communication: viremic control is independent of repeated low-dose SHIVSF162p3 exposures. AIDS Res. Hum. Retroviruses 30, 1125\u20131129 (2014).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"471_CR76","doi-asserted-by":"crossref","first-page":"eaaf1483","DOI":"10.1126\/scitranslmed.aaf1483","volume":"9","author":"MS Parsons","year":"2017","unstructured":"Parsons, M. S. et al. Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection. Sci. Transl. Med. 9, eaaf1483 (2017).","journal-title":"Sci. Transl. Med."},{"key":"471_CR77","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01420-19","volume":"94","author":"S Khanal","year":"2019","unstructured":"Khanal, S. et al. In vivo validation of the viral barcoding of SIVmac239 and the development of new barcoded SIV and subtype B and C SHIVs. J. Virol. 94, e01420-19 (2019).","journal-title":"J. Virol."},{"key":"471_CR78","doi-asserted-by":"crossref","first-page":"eaav7116","DOI":"10.1126\/sciadv.aav7116","volume":"5","author":"C Deleage","year":"2019","unstructured":"Deleage, C. et al. Defining early SIV replication and dissemination dynamics following vaginal transmission. Sci. Adv. 5, eaav7116 (2019).","journal-title":"Sci. Adv."}],"container-title":["Nature Reviews Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41577-020-00471-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41577-020-00471-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41577-020-00471-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:59:08Z","timestamp":1684619948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41577-020-00471-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,2]]},"references-count":78,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["471"],"URL":"https:\/\/doi.org\/10.1038\/s41577-020-00471-1","relation":{},"ISSN":["1474-1733","1474-1741"],"issn-type":[{"value":"1474-1733","type":"print"},{"value":"1474-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,2]]},"assertion":[{"value":"14 October 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}